Skip to content
★ Sign in to follow
SK

Sichuan Kelun Pharmaceutical Co., Ltd. Stock: price and insider trades · China

科伦药业

CN·Mcap CN¥66.5BHealth Care

No insider purchase over the last 90 days. The latest, by 刘思川, was filed 12 Apr 2022.

Sichuan Kelun Pharmaceutical Co., Ltd.: what insiders have been doing

Sichuan Kelun Pharmaceutical Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). Sichuan Kelun Pharmaceutical Co., Ltd. has had no insider filing for more than a year; the last one goes back to 12 April 2022.

Looking back to 2021, when coverage begins, insiders filed 7 purchases and no sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
7
Thresholds
n/a
Buy Volume
€2M
7 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 12 Apr 2022 · 1673 days ago · €238k
    +86.7%
    Entry CN¥16.00 · Close at T+365 CN¥29.87
  • Filed 02 Jul 2021 · 1957 days ago · €26k
    -4.3%
    Entry CN¥19.94 · Close at T+365 CN¥19.08
  • Filed 02 Jul 2021 · 1957 days ago · €51k
    -4.3%
    Entry CN¥19.94 · Close at T+365 CN¥19.08

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 12,794 of 26,911 companies
52.7
score / 100
Value
40
Quality
65
FCF yld1.5%
Earn yld2.6%
EV/EBITDA17.9x
ROE7.5%
Gross mgn48%
Net mgn9.2%
Debt/EBITDA0.9x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥41.78
Analyst consensus
7 analysts
1.44/5
CN¥45.80Target CN¥52.62(+26%)CN¥61.00
Income statement
RevenueCN¥18.5B
Gross profitCN¥8.9B48% margin
EBITDACN¥3.9B21% margin
Net incomeCN¥1.7B10.0% margin
Valuation
PER (trailing)35.7x
PER (forward)28.5x
P/Book2.7x
Beta-0.20
Balance sheet & cash
Market capCN¥66.5B
Total debtCN¥3.5B
Free Cash FlowCN¥1B
Debt / Equity17%
Profitability & ownership
ROE7.5%
ROA2.3%
% insiders33.2%
% institutions16.4%
Last declaration on 12 April 2022
Declarations7 total
  • ▲
    董事,高管Executives
    2M CNY9SZSE
    100,000 shares15.7% of flowA股XSHESZSE:173000005428776300
    Canonical exit: 11 Jul 2022 (T+90)
  • ▲
    董事,高管Executives
    2M CNY24SZSE
    100,000 shares16.2% of flowA股XSHESZSE:173000004565785400
    Canonical exit: 13 Oct 2021 (T+90)
  • ▲
    董事,总经理Executives
    2M CNY39SZSE
    100,000 shares16.6% of flowA股XSHESZSE:173000004560250750
    Canonical exit: 11 Oct 2021 (T+90)
  • ▲
    董事,总经理Executives
    970,500 CNY38SZSE
    50,000 shares8.4% of flowA股XSHESZSE:173000004549240350
    Canonical exit: 6 Oct 2021 (T+90)
  • ▲
    副总经理,财务总监Executives
    196,600 CNY45SZSE
    10,000 shares100.0% of flowA股XSHESZSE:173000005429993660
    Canonical exit: 30 Sept 2021 (T+90)
  • ▲
    董事,总经理Executives
    5M CNY41SZSE
    253,900 shares43.1% of flowA股XSHESZSE:173000004537262750
    Canonical exit: 30 Sept 2021 (T+90)
  • ▲
    副总经理,董事会秘书Executives
    392,000 CNY45SZSE
    20,000 shares100.0% of flowA股XSHESZSE:173000005429992400
    Canonical exit: 30 Sept 2021 (T+90)

7 of 7 declarations

About Sichuan Kelun Pharmaceutical Co., Ltd.

Kanglong Pharmaceutical is a Chinese company operating in the healthcare and pharmaceutical sector. It focuses on the research, development, and production of innovative drugs.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations